This article is more than 5 years old. Information may no longer be current.

Novagali Pharma cleared to begin phase 3 trial of dry eye treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EVRY, France — The U.S. Food and Drug Administration has cleared Novagali Pharma to initiate a phase 3 trial investigating Nova22007, a topical cyclosporine A-containing treatment for dry eye syndrome, the company announced in a press release.

Nova22007 is a proprietary cationic emulsion that enables cyclosporine A to penetrate ocular surface tissues.

The company is evaluating the product for treating patients with moderate to severe dry eye syndrome. Specifically, the planned, double-masked, randomized, vehicle-controlled study will evaluate Nova22007 for relieving objective and subjective symptoms of dry eye, according to the release.